SCHEMBL13627987

SCHEMBL13627987

Cc1cc(C)c2c(c1)/C(=N/O)C(=O)N2Cc1ccccc1C#N

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIN1 Q05586 3/20 0.38
GRIN2B Q13224 3/20 0.38
NOX4 Q9NPH5 1/20 0.37
MAPT P10636 3/20 0.36
TP53 P04637 2/20 0.36
C5AR1 P21730 1/20 0.35
ALDH1A1 P00352 2/20 0.35
GALR3 O60755 1/20 0.35
RAB9A P51151 1/20 0.35
BACE1 P56817 1/20 0.35
THRB P10828 2/20 0.34
COMT P21964 1/20 0.34
TSHR P16473 2/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
MEN1 O00255 1/20 0.33
POLB P06746 1/20 0.33
CYP2C9 P11712 1/20 0.33
APEX1 P27695 1/20 0.33
APOBEC3A P31941 1/20 0.33
CYP2C19 P33261 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13627997 0.89 GRIN1 (0.36) GRIN1GRIN2BNOX4MAPTTP53
SCHEMBL13627952 0.78 ALDH1A1 (0.41) NOX4MAPTALDH1A1GALR3RAB9A
SCHEMBL13628009 0.76 KMT2A (0.48) GRIN1GRIN2BMAPTTP53ALDH1A1
SCHEMBL13627973 0.75 CHRM5 (0.47) GRIN1GRIN2BNOX4ALDH1A1THRB
SCHEMBL13627989 0.72 ALDH1A1 (0.40) MAPTTP53ALDH1A1SMN1; SMN2MEN1
SCHEMBL13627985 0.72 CHRM5 (0.48) MAPTTP53ALDH1A1TSHRSMN1; SMN2
SCHEMBL13627993 0.72 CMA1 (0.51) MAPTTP53ALDH1A1SMN1; SMN2MEN1
SCHEMBL13627991 0.71 TP53 (0.46) MAPTTP53
SCHEMBL13637765 0.70 MAPT (0.37) MAPTTP53ALDH1A1SMN1; SMN2MEN1
SCHEMBL13910738 0.70 SMN1; SMN2 (0.45) MAPTTP53ALDH1A1RAB9ATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7612065-B2 Inhibitors of c-JUN N-terminal kinases (JNK) VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-11-03 US disclosed
US-7612065-B2 Inhibitors of c-JUN N-terminal kinases (JNK) VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-11-03 US disclosed
US-20080033022-A1 Inhibitors of c-Jun N-terminal kinases (JNK) SALITURO FRANCESCO G 2008-02-07 US disclosed
US-20080033022-A1 Inhibitors of c-Jun N-terminal kinases (JNK) SALITURO FRANCESCO G 2008-02-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080033022-A1 Inhibitors of c-Jun N-terminal kinases (JNK) MAP3K1, JUN, MAP3K7 GRIN1 2094/4885GRIN2B 3466/4885NOX4 1532/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.